CYBN Helus Pharma Inc.: institutional ownership and insider trading
Over the last 12 months insiders bought $9.67M and sold $0 on the open market.
Recent CYBN insider trades
- Sep 29, 2026: Cavers Greg bought 3,000 shares ($38.7K)
- Sep 21, 2026: Halstead Michael bought 100,000 shares ($1.35M)
- Sep 8, 2026: So Eric H. L. bought 100,000 shares ($1.24M)
- Sep 8, 2026: Glavine Paul bought 100,000 shares ($1.25M)
5%+ owners
- Venrock Healthcare Capital Partners III, L.P.: 9.9% (Schedule 13G, filed Nov 7, 2025)
- Glavine Paul: 5.8% (Schedule 13D, filed Sep 9, 2026)
- So Eric H. L.: 5.8% (Schedule 13D, filed Sep 9, 2026)
- Millennium Management LLC: 5.7% (Schedule 13G/A, filed Apr 22, 2026)
- Adage Capital Management, L.P.: 5.3% (Schedule 13G, filed Aug 12, 2026)
Are insiders buying or selling CYBN?
Over the last 12 months insiders bought $9.67M and sold $0 of Helus Pharma Inc. stock on the open market (SEC Form 4).